RON is associated with tumor progression via the inhibition of apoptosis and cell cycle arrest in human gastric cancer

Pathology International

Volumn 62, Issue 2, 2012, Pages 127-136

  Song, Young A ^a   Park, Young Lan ^a   Kim, Kyu Yeol ^a   Myung, Eun ^a   Chung, Cho Yun ^a   Cho, Sung Bum ^a   Lee, Wan Sik ^a   Jung, Young Do ^a   Kweon, Sun Seog ^a   Joo, Young Eun ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Apoptosis; Cell cycle; Prognosis; RON; Stomach neoplasm; Tumor metastasis

Indexed keywords

CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; PROTEIN TYROSINE KINASE; RECEPTEUR D'ORIGINE NANTAIS RECEPTOR TYROSINE KINASE; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CANCER STAGING; CELL CYCLE ARREST; CELL FUNCTION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH CANCER; SURVIVAL; TUMOR CELL; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84855959922     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2011.02765.x     Document Type: Article

References (39)

1. Kuwahara A, Takachi R, Tsubono Y, Sasazuki S, Inoue M, Tsugane S, JPHC Study Group. Socioeconomic status and gastric cancer survival in Japan. Gastric Cancer 2010; 13: 222-30.
2. Krejs GJ. Gastric cancer: Epidemiology and risk factors. Dig Dis 2010; 28: 600-3.
3. Ahn HS, Lee HJ, Yoo MW etal. Changes in clinicopathological features and survival after gastrectomy for gastric cancer over a 20-year period. Br J Surg 2011; 98: 255-60.
4. Allan AL, Vantyghem SA, Tuck AB, Chambers AF. Tumor dormancy and cancer stem cells: Implications for the biology and treatment of breast cancer metastasis. Breast Dis 2006; 26: 87-98.
5. Townson JL, Chambers AF. Dormancy of solitary metastatic cells. Cell Cycle 2006; 5: 1744-50.
6. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563-72.
7. Lu Y, Yao HP, Wang MH. Multiple variants of the RON receptor tyrosine kinase: Biochemical properties, tumorigenic activities, and potential drug targets. Cancer Lett 2007; 257: 157-64.
8. Yao HP, Luo YL, Feng L etal. Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase. Cancer Biol Ther 2006; 5: 1179-86.
9. Leonis MA, Thobe MN, Waltz SE. Ron-receptor tyrosine kinase in tumorigenesis and metastasis. Future Oncol 2007; 3: 441-8.
10. Camp ER, Liu W, Fan F, Yang A, Somcio R, Ellis LM. RON, a tyrosine kinase receptor involved in tumor progression and metastasis. Ann Surg Oncol 2005; 12: 273-81.
11. Wang MH, Yao HP, Zhou YQ. Oncogenesis of RON receptor tyrosine kinase: A molecular target for malignant epithelial cancers. Acta Pharmacol Sin 2006; 27: 641-50.
12. Wang MH, Wang D, Chen YQ. Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. Carcinogenesis 2003; 24: 1291-300.
13. Wagh PK, Peace BE, Waltz SE. Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Adv Cancer Res 2008; 100: 1-33.
14. Danilkovitch-Miagkova A. Oncogenic signaling pathways activated by RON receptor tyrosine kinase. Curr Cancer Drug Targets 2003; 3: 31-40.
15. Chen YQ, Zhou YQ, Fu LH, Wang D, Wang MH. Multiple pulmonary adenomas in the lung of transgenic mice overexpressing the RON receptor tyrosine kinase. Recepteur d'origine nantais. Carcinogenesis 2002; 23: 1811-19.
16. Peace BE, Toney-Earley K, Collins MH, Waltz SE. Ron receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer. Cancer Res 2005; 65: 1285-93.
17. Chen YQ, Zhou YQ, Angeloni D, Kurtz AL, Qiang XZ, Wang MH. Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines. Exp Cell Res 2000; 261: 229-38.
18. Maggiora P, Marchio S, Stella MC, etal. Overexpression of the RON gene in human breast carcinoma. Oncogene 1998; 16: 2927-33.
19. Willett CG, Wang MH, Emanuel RL etal. Macrophage-stimulating protein and its receptor in non-small cell lung tumors: Induction of receptor tyrosine phosphorylation and cell migration. Am J Respir Cell Mol Biol 1998; 18: 489-96.
20. Maggiora P, Lorenzato A, Fracchioli S etal. The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp Cell Res 2003; 288: 382-9.
21. Thomas RM, Toney K, Fenoglio-Preiser C etal. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res 2007; 67: 6075-82.
22. Zhou D, Pan G, Zheng C, Zheng J, Yian L, Teng X. Expression of the RON receptor tyrosine kinase and its association with gastric carcinoma versus normal gastric tissues. BMC Cancer 2008; 8: 353.
23. Cheng HL, Liu HS, Lin YJ etal. Coexpression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br J Cancer 2005; 92: 1906-14.
24. Li Z, Yao H, Guin S, Padhye SS, Zhou YQ, Wang MH. Monoclonal antibodies-induced down-regulation of RON-receptor tyrosine kinase diminishes tumorigenic activities of colon cancer cells. Int J Oncol 2010; 37: 473-82.
25. Gunes Z, Zucconi A, Cioce M etal. Isolation of fully human antagonistic antibodies showing efficient block of downstream signaling and cell migration. Trans Oncol 2011; 4: 38-46.
26. Lauren P. The two histologic main types of gastric carcinoma. Acta Pathol Microbiol Scand 1965; 63: 31-49.
27. Watanabe H, Jass JR, Sobin LH. WHO International Histologic Classification of Tumors: The Histologic Typing of Oesophageal and Gastric Tumors. Berlin, Heidelberg, New York, Paris, Tokyo, Hong Kong: Springer-Verlag, 1990.
28. American Joint Committee on Cancer. Manual for Staging Cancer. In: Fleming ID, Cooper JS, Henson DE, eds. Stomach Cancer. Philadelphia, PA: Lippincott-Raven, 1997; 71-6.
29. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005; 9: 59-71.
30. Schultz DR, Harrington WJ Jr. Apoptosis: Programmed cell death at a molecular level. Semin Arthritis Rheum 2003; 32: 345-69.
31. Morgan DO. Principles of CDK regulation. Nature 1995; 374: 131-4.
32. Grana X, Reddy EP. Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995; 11: 211-9.
33. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-7.
34. Johnson N, Shapiro GI. Cyclin-dependent kinases (cdks) and the DNA damage response: Rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors. Expert Opin Ther Targets 2010; 14: 1199-212.
35. Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 2011; 75: 50-83.
36. Keshet Y, Seger R. The MAP kinase signaling cascades: A system of hundreds of components regulates a diverse array of physiological functions. Methods Mol Biol 2010; 661: 3-38.
37. Sullivan RJ, Atkins MB. Molecular targeted therapy for patients with melanoma: The promise of MAPK pathway inhibition and beyond. Expert Opin Investig Drugs 2010; 19: 1205-16.
38. Pratilas CA, Solit DB. Targeting the mitogen-activated protein kinase pathway: Physiological feedback and drug response. Clin Cancer Res 2010; 16: 3329-34.
39. Haagenson KK, Wu GS. Mitogen activated protein kinase phosphatases and cancer. Cancer Biol Ther 2010; 9: 337-40.